1. Fischer A, du Bois R. Interstitial lung disease in connective
tissue disorders. Lancet 2012;380 (9842):689-98.
2. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell
DM, Harrison NK, Hirani N, Hubbard R, Lake F,
Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher
ML; British Thoracic Society Interstitial Lung Disease
Guideline Group, British Thoracic Society Standards
of Care Committee; Thoracic Society of Australia;
New Zealand Thoracic Society; Irish Thoracic Society.
Interstitial lung disease guideline: The British Thoracic
Society in collaboration with the Thoracic Society of
Australia and New Zealand and the Irish Thoracic
Society. Thorax. 2008; Suppl 5:v1-58.
3. Ruano CA, Lucas RN, Leal CI, Lourenço J, Pinheiro S,
Fernandes O,Ruano CA, Lucas RN, Leal CI, Lourenço
J, Pinheiro S, Fernandes O, Figueiredo L. Thoracic
manifestations of connective tissue diseases. Curr Probl
Diagn Radiol 2015;44(1):47-59.
4. Wang JX, Du CG. A retrospective study of clinical
characteristics of interstitial lung disease associated with
rheumatoid arthritis in Chinese patients. Med Sci Monit
2015; 21:708-15.
5. Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB,
Aalokken TM, Gran TJ. Clinical pulmonary involvement
in primary Sjogren’s syndrome: Prevalence, quality of life
and mortality-a retrospective study based on registry data.
Rheumatology (Oxford) 2013;52(1):173-9.
6. Yazisiz V, Arslan G, Ozbudak IH, Türker S, Erbasan F,
Avci AB, Ozbudak O, Terzioğlu E. Lung involvement in
patients with primary Sjögren’s syndrome: What are the
predictors? Rheumatol Int 2010;30(10):1317-24.
7. Bertoli AM, Vila LM, Apte M, Fessler BJ, Bastian HM,
Reveille JD, Alarcon GS. LUMINA Study Group.
Systemic lupus erythematosus in a multiethnic US Cohort
LUMINA XLVIII: Factors predictive of pulmonary
damage. Lupus 2007;16(6):410-7.
8. Jain S, Shahane A, Derk CT. Interstitial lung disease in
systemic sclerosis: Patho-physiology, current and new
advances in therapy. Inflamm Allergy Drug Targets
2012;11(4): 266-77.
9. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira
PE, Bancel DF, Allanore Y, Müller-Ladner U, Distler O,
Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva
L, Gurman AB, Damjanov N, Mueller A, Valentini G,
Riemekasten G, Tikly M, Hummers L, Henriques MJ,
Caramaschi P, Scheja A, Rozman B, Ton E, Kumánovics
G, Coleiro B, Feierl E, Szucs G, Von Mühlen CA, Riccieri
V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho
PC, Kötter I, Simsek I, de la Pena Lefebvre PG, Hachulla
E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J,
Walker UA. Causes and risk factors for death in systemic
sclerosis: A study from the EULAR Scleroderma Trials
and Research (EUSTAR) database. Ann Rheum Dis
2010;69(10):1809-15.
10. Olson AL, Swigris JJ, Sprunger DB, Fischer A,
Fernandez-Perez ER, Solomon J, Murpy J, Cohen M,
Raghu G, Brown KK. Rheumatoid arthritis-interstitial
lung disease-associated mortality. Am J Respir Crit Care
Med 2011;183:372–8.
11. Komocsi A, Vorobcsuk A, Faludi R, Pintér T, Lenkey
Z, Költo G, Crizjak L. The impact of cardiopulmonary
manifestations on the mortality of SSc: A systematic
review and meta-analysis of observational studies.
Rheumatology (Oxford) 2012;51:1027-36.
12. Saketkoo LA, Matteson EL, Brown KK, Seibold JR,
Strand V. Developing disease activity and response
criteria in connective tissue disease related interstitial lung
disease. J Rheumatol 2011;38(7):1514-8.
13. Wells AU, Denton CP. Interstitial lung disease in
connective tissue disease-mechanisms and management.
Nat Rev Rheumatol 2014;10(12):728-39.
14. American Thoracic Society/European Respiratory
and Society. International Multidisciplinary Consensus
Classification of the Idiopathic Interstitial Pneumonia.
Am J Respir Crit Care Med 2002;165: 277-304.
15. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang
BH, Ryu JH, King TE, Collard HR, Kim DS, Lee LS.
Rheumatoid arthritis-associated interstitial lung disease:
Radiologic identification of usual interstitial pneumonia
pattern. Radiology 2014; 270(2):583-8.
16. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth
MD, Furst DE; Scleroderma Lung Study Research
Group. Cyclophosphamide versus placebo in scleroderma
lung disease. N Engl J Med 2006;354: 2655-66.
17. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands
P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh
NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton
CP, Wells AU, Black CM, du Bois RM. A multicenter,
prospective, randomized, double-blind, placebocontrolled
trial of corticosteroids and intravenous
cyclophosphamide followed by oral azathioprine for the
treatment of pulmonary fibrosis in scleroderma. Arthritis
Rheum 2006;54(12):3962-70.
18. Solomon JJ, Chartrand S, Fischer A. Current approach
to connective tissue disease-associated interstitial lung
disease. Curr Opin Pulm Med 2014;20(5):449-56.
79
Interstitial Lung Diseases in Rheumatology Practice: A Single Center Experience
Akd Tıp D / Akd Med J / 2017; 2: 71-81
19. Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer
D, Renzoni EA, Hansell DM, du Bois RM, Wells AU.
Marginal decline in forced vital capacity is associated with
a poor outcome in idiopathic pulmonary fibrosis. Eur
Respir J 2010;35:830-6.
20. Colaci M, Sebastiani M, Manfredi A, Giuggioli D,
Cassone G, Manzini CU, Chizzoni C, Cerri S, Ferri
C. Lung involvement in systemic sclerosis: role of high
resolution computed tomography and its relationship
with other pulmonary and clinico-serological features. J
Biol Regul Homeost Agents 2014;28(3):481-8.
21. Taouli B, Brauner MW, Mourey I, Lemouchi D, Grenier
PA. Thin-section chest CT findings of primary Sjogren’s
syndrome: Correlation with pulmonary function. Eur
Radiol 2002;12:1504-11.
22. Hyldgaard C. A cohort study of Danish patients with
interstitial lung diseases: burden, severity, treatment and
survival. Dan Med J 2015;62(4):B5069.
23. Thomeer MJ, Costabe U, Rizzato G, Poletti V, Demedts
M. Comparison of registries of interstitial lung diseases
in three European countries. Eur Respir J 2001;32
Suppl:114-8.
24. Thomeer M, Demedts M, Vandeurzen K; VRGT
Working Group on Interstitial Lung Diseases. Registration
of interstitial lung diseases by 20 centres of respiratory
medicine in Flanders. Acta Clin Belg 2001;56(3):163-72.
25. Migita K, Arai T, Jiuchi Y, Izumi Y, Iwanaga N, Kawahara
C, Suematsu E, Miyamura T, Tsutani H, Kawabe Y,
Matsumura R, Mori S, Ohshima S, Yoshizawa S, Suenaga
Y, Ogushi F, Kawabata M, Furukawa H, Matsui T, Bito
S, Tohma S. Predictors of mortality in patients with
interstitial lung disease treated with corticosteroids: Results
from a cohort study. Medicine (Baltimore) 2014;93(26):
e175.
26. Musellim B, Okumus G, Uzaslan E, Akgün M, Cetinkaya
E, Turan O, Akkoçlu A, Hazar A, Kokturk N, Çalışır HC.
Turkish Interstitial Lung Diseases Group Epidemiology
and distribution of interstitial lung diseases in Turkey.
Clin Respir J 2014; 8(1):55-62.
27. Yazisiz V, Avci AB, Erbasan F, Kiriş E, Terzioğlu E.
Diagnostic performance of minor salivary gland biopsy,
serological and clinical data in Sjögren’s syndrome: A
retrospective analysis. Rheumatol Int 2009;29(4):403-9.
28. Pennell LM, Galligan CL, Fish EN. Sex affects immunity.
J Autoimmun 2012;38:282-91.
29. de Lauretis A, Veeraraghavan S, Renzoni E. Review
series: Aspects of interstitial lung disease: Connective
tissue disease-associated interstitial lung disease: How
does it differ from IPF? How should the clinical approach
differ? Chron Respir Dis 2011;8(1):53-82.
30. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS.
Pathologic and radiologic differences between idiopathic
and collagen vascular disease-related usual interstitial
pneumonia. Chest 2009;136(1):23-30.
31. Alhamad EH. Interstitial lung diseases in Saudi Arabia: A
single-center study.Ann Thorac Med 2013;8(1):33-7.
32. Kazerooni EA, Martinez FJ, Flint A, Jamadar DA, Gross
BH, Spizarny DL, Cascade PN, Whyte RI, Lynch JP 3rd,
Toews G. Thin-section CT obtained at 10-mm increments
versus limited three-level thin-section CT for idiopathic
pulmonary fibrosis: Correlation with pathologic scoring.
AJR Am J Roentgenol 1997;169(4):977-83.
33. Kadoch MA, Cham MD, Beasley MB, Ward TJ, Jacobi
AH, Eber CD, Padilla LM. Idiopathic interstitial
pneumonias: A radiology-pathology correlation based on
the revised 2013 American Thoracic Society-European
Respiratory Society classification system. Curr Probl
Diagn Radiol 2015;44(1):15-25.
34. Latsi PI, du Bois RM, Nicholson AG, Colby TV,
Bizirtzoglou D, Nikolakopoulou A, Veeraraghavan S,
Hansell DM, Wells AU. Fibrotic idiopathic interstitial
pneumonia: the prognostic value of longitudinal functional
trends. Am J Respir Crit Care Med 2003;168(5):531-7.
35. Ando K, Motojima S, Doi T, Nagaako T, Kaneko
N, Aoshima M, Takahaski T. Effect of glucocorticoid
monotherapy on pulmonary function and survival in
Japanese patients with scleroderma-related interstitial
lung disease. Respir Investig 2013;51:69–75.
36. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst
DE, Silver RM; Scleroderma Lung Study Research
Group. Cyclophosphamide versus placebo in scleroderma
lung disease. N Engl J Med 2006;22;354(25):2655-66.
37. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A
randomized unblinded trial of cyclophosphamide versus
azathioprine in the treatment of systemic sclerosis. Clin
Rheumatol 2006;25 (2): 205-12.
38. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros
D, Dantis PC. Intravenous cyclophosphamide pulse
therapy for the treatment of lung disease associated with
scleroderma. Clin Rheumatol 1999;18(6): 455-61.
39. Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger
TA Jr. Therapy for severe interstitial lung disease in
systemic sclerosis. A retrospective study. Arthritis Rheum
1994;37(9):1290-6.
40. Espinosa G, Simeón CP, Plasín MÁ, Xaubet A, Munoz
X, Fonollosa V, Cervera R, Vilardel M. Efficacy
of cyclophosphamide in the treatment of interstitial
lung disease associated with systemic sclerosis. Arch
Bronconeumol 2011;47(5):239-45.
41. Balbir-Gurman A, Yigla M, Guralnik L, Hardak E,
Solomonov A, Rozin AP, Toledone K, Dagan A, Bishara
R, Markovitz D, Nahir MA, Braun-Moscovici Y. Longterm
follow-up of patients with scleroderma interstitial
lung disease treated with intravenous cyclophosphamide
pulse therapy: A single-center experience. Isr Med Assoc J
2015;17(3):150-6.
42. Bérezné A, Ranque B, Valeyre D, Brauner M, Allanore Y,
Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans
80
Erbasan F. et al.
Akd Tıp D / Akd Med J / 2017; 2: 71-81
J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A,
Cabane J, Guillevin L, Mouthon L. Therapeutic strategy
combining intravenous cyclophosphamide followed by
oral azathioprine to treat worsening interstitial lung disease
associated with systemic sclerosis: A retrospective multicenter
open-label study. J Rheumatol 2008;35: 1064–72.
43. Gonzalez-Nieto JA, Martin-Suarez IJ, Gil-Muñoz FL.
Efficacy of mycophenolate associated with methotrexate
as a maintenance treatment for systemic sclerosis
associated interstitial lung disease. Arch Bronconeumol
2011;47(11): 575.
44. Tochimoto A, Kawaguchi Y, Hara M, Tataishi M,
Fucasawa C, Tagaki K, Nishimagi E, Ota Y, Katsumata
Y, Gono T, Tanaka E, Yamanaka H. Efficacy and safety
of intravenous cyclophosphamide pulse therapy with oral
prednisolone in the treatment of interstitial lung disease
with systemic sclerosis: 4-year follow-up. Mod Rheumatol
2011;21:296-301.
45. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA.
Cyclophosphamide is associated with pulmonary function
and survival benefit in patients with scleroderma and
alveolitis. Ann Intern Med 2000;132(12): 947-54.
46. Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T,
Origgi L, Scorza R. Oral cyclophosphamide improves
pulmonary function in scleroderma patients with fibrosing
alveolitis: Experience in one centre. Clin Rheumatol
2007;26(2): 168-72.
47. Airò P, Danieli E, Rossi M, Frassi M, Cavazzana I, Scarsi
M, Grottolo A, Franceschini F, Zambruni A. Intravenous
cyclophosphamide for interstitial lung disease associated to
systemic sclerosis: Results with an 18-month long protocol
including a maintenance phase. Clin Exp Rheumatol
2007;25(2): 293-6.
48. Pakas I, Ioannidis JP, Malagari K, Skopouli FN,
Moutsopoulos HM, Vlachoyiannopoulos PG.
Cyclophosphamide with low or high dose prednisolone for
systemic sclerosis lung disease. J Rheumatol 2002;29(2):
298-304.
49. Silver RM, Warrick JH, Kinsella MB, Staudt LS,
Baumann MH, Strange C. Cyclophosphamide and lowdose
prednisone therapy in patients with systemic sclerosis
(scleroderma) with interstitial lung disease. J Rheumatol
2013;20(5).838-44.
50. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P,
Conforti ML, Fulminis A, De Luca A, Farina G, Candela
M, Generini S, De Francisci A, Tirri E, Proietti M, Bombardieri
S, Gabrielli A, Tonietti G, Cerinic MM. Cyclophosphamide
pulse regimen in. The treatment of alveolitis
in systemic sclerosis. J Rheumatol 2002;29(4):731-6.
51. Griffiths B, Miles S, Moss H, Robertson R, Veale D,
Emery P. Systemic sclerosis and interstitial lung disease:
A pilot study using pulse intravenous methylprednisolone
and cyclophosphamide to assess the effect on high
resolution computed tomography scan and lung function.
J Rheumatol 2002;29(11):2371-8.
52. Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L.
Persistence of abnormal bronchoalveolar lavage findings
after cyclophosphamide treatment in scleroderma
patients with interstitial lung disease. Arthritis Rheum
2007;56(12):4195-202.
53. Domiciano DS, Bonfá E, Borges CT, Kairalla RA,
Capelozzi VL, Parra E, Christmann RB. A long-term
prospective randomized controlled study of non-specific
interstitial pneumonia (NSIP) treatment in scleroderma.
Clin Rheumatol 2011;30 (2): 223-9.
54. Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, et
al.Intravenous cyclophosphamide pulse therapy in the
treatment of systemic sclerosis-related interstitial lung
disease: A long term study. Open Respir Med J 2008;2:
39-45.
55. Yiannopoulos G, Pastromas V, Antonopoulos I,
Katsiberis G, Kalliolias G, Liossis SN, Andonopoulos AP.
Combination of intravenous pulses of cyclophosphamide
and methylprednisolone in patients with systemic sclerosis
and interstitial lung disease. Rheumatol Int 2007;27(4):
357-61.
56. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved
pulmonary function in systemic sclerosis after treatment
with cyclophosphamide. Arthritis Rheum 1994;37:
729-35.
57. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna
D, Kleerup EC, Goldin J, Arriola E, Volkmann ER,
Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F,
Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel
B, Phillips K, Martinez F, Golden J, Connolly MK, Varga
J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan
R, Theodore A, Simms R, Volkov S, Schraufnagel DE,
Scholand MB, Frech T, Molitor JA, Highland K, Read
CA, Fritzler MJ, Kim GH, Tseng CH, Elashoff RM;
Sclerodema Lung Study II Investigators. Mycophenolate
mofetil versus oral cyclophosphamide in sclerodermarelated
interstitial lung disease (SLS II): A randomised
controlled, double-blind, parallel group trial. Lancet
Respir Med 2016;4(9):708-19.
58. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate
mofetil on pulmonary function in scleroderma-associated
interstitial lung disease. Chest 2008;133:455-60.
59. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas
LI. Mycophenolate mofetil in systemic sclerosis-associated
interstitial lung disease. Clin Rheumatol 2010;29:1167-8.
60. Zamora AC, Wolters PJ, Collard HR, Connolly MK,
Elicker BM, Webb WR, King TE Jr, Golden JA. Use of
mycophenolate mofetil to treat scleroderma-associated
interstitial lung disease. Respir Med 2008;102:150-5.
61. Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.
Two-year experience with mycophenolate mofetil in
patients with scleroderma lung disease: A case series. Int J
Rheum Dis 2014;17(8):923-8.
81
Interstitial Lung Diseases in Rheumatology Practice: A Single Center Experience
Akd Tıp D / Akd Med J / 2017; 2: 71-81
62. Fischer A, Brown KK, Du Bois RM, Frankel SK,
Cosgrove GP, Fernandez-Perez ER, Huie TJ,
Krishnamoorthy M, Meehan RT, Olson AL, Solomon JJ,
Swigris JJ. Mycophenolate mofetil improves lung function
in connective tissue disease-associated interstitial lung
disease. J Rheumatol 2013;40:640-6.
63. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis
A, Wickremasinghe M, Nicholson AG, Hansell DM,
Wells AU, Renzoni EA. Rituximab in severe, treatmentrefractory
interstitial lung disease. Respirology
2014;19:353-9.
64. Conway R, Low C, Coughlan RJ, O’Donnell MJ, Carey
JJ. Methotrexate and lung disease in rheumatoid arthritis:
A meta-analysis of randomized controlled trials. Arthritis
Rheumatol 2014; 66(4):803-12.
65. van den Hoogen FH, Boerbooms AM, Swaak AJ,
Rasker JJ, van Lier HJ, van de Putte LB. Comparison of
methotrexate with placebo in the treatment of systemic
sclerosis: a 24 week randomized double-blind trial,
followed by a 24 week observational trial. Br J Rheumatol
1996;35:364-72.
66. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M,
Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon
D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst
DE. A randomized, controlled trial of methotrexate
versus placebo in early diffuse scleroderma. Arthritis
Rheum 2001;44:1351-8.
Thank you for copying data from http://www.arastirmax.com
